A Phase 4 interventional study of everolimus in Pancreatic Neuroendocrine Tumors, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-02-10.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate safety and efficacy of everolimus (Afinitor®) in Chinese adult patients with local advanced or metastatic, well differentiated progressive pancreatic neuroendocrine tumors.
This was an open-label, multicenter, single-arm clinical study to evaluate the safety and efficacy of everolimus in Chinese adult patients with locally advanced, unresectable or metastatic, well differentiated progressive pancreatic neuroendocrine tumors. The inclusion and exclusion criteria, as well as the dosing and dose modification criteria are designed according to the approved Chinese Package Insert. The planned sample size of the study was approximately 60 subjects.
Subjects who were eligible received the treatment with everolimus provided by sponsor to treat pNET and followed the visit schedule in the protocol to collect safety and efficacy data until progression of disease, unacceptable toxicity, death, protocol deviation or other reason that may lead to discontinuation before the end of study. All subjects were followed-up for survival status every 6 months by the investigator until death, lost to follow-up, withdrawal of consent for survival or end of study.
The "End of study" is defined as either at least 75% of subjects have completed survival follow up or all subjects discontinued study treatment or the last subject finished 5-year survival follow up, whichever comes first. Final analysis was conducted at the end of the study.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were instructed to take everolimus at a starting dose of 10 mg orally once daily. However, dose adjustments were permitted in order to allow the participant to continue the study treatment.
Drug: everolimus
Participants were instructed to take everolimus at a starting dose of 10 mg orally once daily. However, dose adjustments were permitted in order to allow the participant to continue the study treatment.
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of participants with treatment emergent adverse events (any AE regardless of seriousness), SAEs, AEs and SAEs on grade 3 or 4, and suspected to be related to the study drug.
Time frame: Adverse events were reported from first dose of study treatment until end of study treatment plus follow up period of 30 days, up to a maximum duration of approximately 5 years.
Overall Survival (OS)
Overall Survival is defined as the time from the start of study treatment to death due to any cause. OS was analyzed using the Kaplan-Meier method.
Time frame: Up to approximately 7 years and 6 months.
Progression Free Survival (PFS) by Investigator Assessment Per RECIST 1.1
Progression free survival is defined as the time from the initiation of study treatment to disease progression or death due to any cause. PFS was analyzed using Kaplan-Meier estimates.
Time frame: Up to approximately 2 years and 9 months
Participants took part in 5 investigative sites in China.
| Milestone | Everolimus |
|---|---|
| Started | 61 |
| Completed | 61 |
| Not completed | 0 |
Number of participants with treatment emergent adverse events (any AE regardless of seriousness), SAEs, AEs and SAEs on grade 3 or 4, and suspected to be related to the study drug.
| Participants | Everolimus |
|---|---|
| AEs | 60 |
| AEs-grade 3/4 | 30 |
| AEs Suspected to be related to the study drug | 58 |
| AEs Suspected to be related to the study drug-grade 3/4 | 19 |
| SAEs | 17 |
| SAEs-grade 3/4 | 11 |
| SAEs Suspected to be related to the study drug | 8 |
| SAEs Suspected to be related to the study drug-grade 3/4 | 5 |
Overall Survival is defined as the time from the start of study treatment to death due to any cause. OS was analyzed using the Kaplan-Meier method.
| months | Everolimus |
|---|---|
| Overall Survival (OS) | 66.56 (39.66 to NA) |
Progression free survival is defined as the time from the initiation of study treatment to disease progression or death due to any cause. PFS was analyzed using Kaplan-Meier estimates.
| months | Everolimus |
|---|---|
| Progression Free Survival (PFS) by Investigator Assessment Per RECIST 1.1 | 16.07 (11.04 to 21.52) |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days (on treatment period), up to a maximum duration of approximately 5 years. All cause mortality was reported until end of study, up to approximately 7 years and 6 months (on treatment plus survival follow-up period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus-on Treatment | 6/61 (9.8%) | 17/61 (27.9%) | 60/61 (98.4%) |
| Everolimus-Survival Follow-up | 22/55 (40%) | — | — |
| Event | Everolimus-on Treatment | Everolimus-Survival Follow-up |
|---|---|---|
| Infectious pneumonitisInfections and infestations | 3/61 | — |
| AstheniaGeneral disorders | 2/61 | — |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 1/61 | — |
| CachexiaMetabolism and nutrition disorders | 1/61 | — |
| Function liver abnormalHepatobiliary disorders | 1/61 | — |
| Anal abscessInfections and infestations | 1/61 | — |
| SepsisInfections and infestations | 1/61 | — |
| Herpes virus infectionInfections and infestations | 1/61 | — |
| Hemorrhage cerebralNervous system disorders | 1/61 | — |
| Hypoglycemic encephalopathyNervous system disorders | 1/61 | — |
| Event | Everolimus-on Treatment | Everolimus-Survival Follow-up |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 30/61 | — |
| Aspartate aminotransferase increasedInvestigations | 27/61 | — |
| Mouth ulcerationGastrointestinal disorders | 24/61 | — |
| StomatitisGastrointestinal disorders | 23/61 | — |
| DiarrhoeaGastrointestinal disorders | 22/61 | — |
| Alanine aminotransferase increasedInvestigations | 18/61 | — |
| White blood cell count decreasedInvestigations | 16/61 | — |
| Neutrophil count decreasedInvestigations | 15/61 | — |
| RashSkin and subcutaneous tissue disorders | 15/61 | — |
| Platelet count decreasedInvestigations | 14/61 | — |
| Age, Continuous(years) | Everolimus |
|---|---|
| Mean | 53.22 ± 14.305 |
| Sex: Female, Male(Participants) | Everolimus |
|---|---|
| Female | 23 |
| Male | 38 |
| Race/Ethnicity, Customized(Participants) | Everolimus |
|---|---|
| Asian | 61 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Ran from Mar 2016 to primary completion in Feb 2024, 95 months.
Results were first posted in Feb 2025, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus